Tweet
GHRP-6
GH-releasing hexapeptide (GHRP-6) is a secratogue that stimulates the release of growth hormone (GH) by acting at both hypothalamic and pituitary sites which has been clinically documented in a wide variety of species in vivo and in vitro. GHRP-6 duplicates the way the growth hormone works in the body. In studies it not only has shown to enhance growth hormone levels, but also increased the pulsatile secretory bursts of GH. Another remarkable trait of GHRP-6 is its increase in normal pulsatile physiological secretion by its hypothalamic action. Initial studies with GHRP-6 suggested that this compound acted primarily on the pituitary gland and was absolutely specific for GH release. More recent studies have qualified both of these assumptions. This peptide has been clinically verified to increase GH levels, increase appetite, raise IGF-1 levels, help sleep cycles and more.
The GHRP-6 is enclosed in an antivirus capsule, which essentially the outer capsule of a virus that contains no actual viral DNA or RNA so it is completely safe. The Antivirus used has been engineered to contain special peptides on it that actually act like an adhesive glue to certain cells in your mouth. These peptides are very important because by adhering to the mucosal cells in your mouth they ensure that the antivirus can inject the GHRP-6 into your cells. The antivirus signals the lipid membrane to open protein channels that actually take the peptide into the cell. Once in the cells the mucosal adhesion peptides are broken off from the peptide we added whether it be IGF, GHRP-6 or whatever. The peptide is now free to be release through the lymphatic system in its biological active form. This means it is carried throughout the blood stream directly from the cells in your mouth. So there is no sudden spike of GHRP-6 your own cells actually regulate its release. It never reaches any digestive enzymes or acids beyond that of the mucus in your moth which is actually at about the same pH used to store GHRP-6 in acetic acid, so claiming that it?s broken down here is ridiculous. The transport of the peptide to the lymphatic system is what results in a slower more controlled release of the peptide over time. A recent study has verified that a 24 hr constant iv infusion of GHRP-6 neurophysiologically (via the central nervous system) activated the GH-IGF-1 axis by activating GH secretory burst mass and amplitude by 7 -to 10-fold and increasing the basal (nonpulsitile) GH secretion by 4.5 fold. For example, significant increases in plasma IGF-1 concentrations were noted after 7 days of GHRP-6 infusion and have even been reported after 7 days of intranasal administration in children and in adults after 7 to 14 days of intranasal hexarelin administration. It is also of interest that long-term administration of hexarelin has been shown to significantly increase circulating GH concentrations as well. The potential clinical utility of these GH secratogues is due to the consistent clinical verification of these findings in individuals of many ages.
Users often administer this product by placing it in a syring and squirting it into the cheeks on the side of the mouth. Users are urged not to do anything to induce excess saliva secretion because this will diminish the absorption rate of the drug by causing a larger portion of it to be flushed down the throat and dissolved by the stomach. Users are instructed not to take this product with food, because this will also greatly hinder the amount of the drug that is actually absorbed by the body. It is also important to note that users shouldn?t brush their teeth or do any kind of mouthwash 30 minutes before or after administration. The basic idea is to keep the mouth as undisturbed and as dry as possible while the hormone has time to seep into the pours on the inner lining of the mouth so that it can be properly absorbed.
GH-releasing hexapeptide (GHRP-6) is a secratogue that stimulates the release of growth hormone (GH) by acting at both hypothalamic and pituitary sites which has been clinically documented in a wide variety of species in vivo and in vitro. GHRP-6 duplicates the way the growth hormone works in the body. In studies it not only has shown to enhance growth hormone levels, but also increased the pulsatile secretory bursts of GH. Another remarkable trait of GHRP-6 is its increase in normal pulsatile physiological secretion by its hypothalamic action. Initial studies with GHRP-6 suggested that this compound acted primarily on the pituitary gland and was absolutely specific for GH release. More recent studies have qualified both of these assumptions. This peptide has been clinically verified to increase GH levels, increase appetite, raise IGF-1 levels, help sleep cycles and more.
The GHRP-6 is enclosed in an antivirus capsule, which essentially the outer capsule of a virus that contains no actual viral DNA or RNA so it is completely safe. The Antivirus used has been engineered to contain special peptides on it that actually act like an adhesive glue to certain cells in your mouth. These peptides are very important because by adhering to the mucosal cells in your mouth they ensure that the antivirus can inject the GHRP-6 into your cells. The antivirus signals the lipid membrane to open protein channels that actually take the peptide into the cell. Once in the cells the mucosal adhesion peptides are broken off from the peptide we added whether it be IGF, GHRP-6 or whatever. The peptide is now free to be release through the lymphatic system in its biological active form. This means it is carried throughout the blood stream directly from the cells in your mouth. So there is no sudden spike of GHRP-6 your own cells actually regulate its release. It never reaches any digestive enzymes or acids beyond that of the mucus in your moth which is actually at about the same pH used to store GHRP-6 in acetic acid, so claiming that it?s broken down here is ridiculous. The transport of the peptide to the lymphatic system is what results in a slower more controlled release of the peptide over time. A recent study has verified that a 24 hr constant iv infusion of GHRP-6 neurophysiologically (via the central nervous system) activated the GH-IGF-1 axis by activating GH secretory burst mass and amplitude by 7 -to 10-fold and increasing the basal (nonpulsitile) GH secretion by 4.5 fold. For example, significant increases in plasma IGF-1 concentrations were noted after 7 days of GHRP-6 infusion and have even been reported after 7 days of intranasal administration in children and in adults after 7 to 14 days of intranasal hexarelin administration. It is also of interest that long-term administration of hexarelin has been shown to significantly increase circulating GH concentrations as well. The potential clinical utility of these GH secratogues is due to the consistent clinical verification of these findings in individuals of many ages.
Users often administer this product by placing it in a syring and squirting it into the cheeks on the side of the mouth. Users are urged not to do anything to induce excess saliva secretion because this will diminish the absorption rate of the drug by causing a larger portion of it to be flushed down the throat and dissolved by the stomach. Users are instructed not to take this product with food, because this will also greatly hinder the amount of the drug that is actually absorbed by the body. It is also important to note that users shouldn?t brush their teeth or do any kind of mouthwash 30 minutes before or after administration. The basic idea is to keep the mouth as undisturbed and as dry as possible while the hormone has time to seep into the pours on the inner lining of the mouth so that it can be properly absorbed.
Comment